Literature DB >> 24599376

Can radioimmunotherapy promote from an orphan drug to daily clinical practice?

Felix M Mottaghy1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24599376     DOI： 10.1007/s00259-014-2722-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  20 in total

1.  Studies directed toward the use of antibodies as carriers of radioactivity for therapy.

Authors:  W F BALE; I L SPAR
Journal:  Adv Biol Med Phys       Date:  1957

2.  In vivo localization of rat organ antibodies in ovaries, adrenals, and other tissues.

Authors:  W F BALE; I L SPAR
Journal:  J Immunol       Date:  1954-09       Impact factor: 5.422

3.  Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.

Authors:  Bernard M Tijink; Dario Neri; C René Leemans; Marianne Budde; Ludger M Dinkelborg; Marijke Stigter-van Walsum; Luciano Zardi; Guus A M S van Dongen
Journal:  J Nucl Med       Date:  2006-07       Impact factor: 10.057

Review 4.  Radiolabeled antibody therapy of B-cell lymphomas.

Authors:  O W Press
Journal:  Semin Oncol       Date:  1999-10       Impact factor: 4.929

5.  Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody.

Authors:  Didier Decaudin; Raphaël Levy; François Lokiec; Franck Morschhauser; Malika Djeridane; Jean Kadouche; Alain Pecking
Journal:  Anticancer Drugs       Date:  2007-07       Impact factor: 2.248

6.  Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.

Authors:  Luigi Aloj; Laura D'Ambrosio; Michela Aurilio; Anna Morisco; Ferdinando Frigeri; Corradina Caraco'; Francesca Di Gennaro; Gaetana Capobianco; Leonardo Giovannoni; Hans D Menssen; Dario Neri; Antonio Pinto; Secondo Lastoria
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

7.  A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma.

Authors:  Gairin Dancey; John Violet; Alessandra Malaroda; Alan J Green; Surinder K Sharma; Roslyn Francis; Shokri Othman; Sweta Parker; John Buscombe; Natalie Griffin; Pei-San Chan; Anmol Malhotra; Nicholas Woodward; Alan Ramsay; Philip Ross; T Andrew Lister; Peter Amlot; Richard Begent; Christopher McNamara
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

8.  Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.

Authors:  Alexander B Stillebroer; Otto C Boerman; Ingrid M E Desar; Marije J Boers-Sonderen; Carla M L van Herpen; Johannes F Langenhuijsen; Peter M Smith-Jones; Egbert Oosterwijk; Wim J G Oyen; Peter F A Mulders
Journal:  Eur Urol       Date:  2012-08-21       Impact factor: 20.096

Review 9.  Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease.

Authors:  H M Vriesendorp; J D Morton; S M Quadri
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701

10.  The role of tenascin-C in tissue injury and tumorigenesis.

Authors:  Kim S Midwood; Gertraud Orend
Journal:  J Cell Commun Signal       Date:  2009-10-17       Impact factor: 5.782
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.